Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma
NCT03298451Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 17
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Oct 2017; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03298451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298451.